
- /
- Supported exchanges
- / US
- / STIM.NASDAQ
Neuronetics Inc (STIM NASDAQ) stock market data APIs
Neuronetics Inc Financial Data Overview
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neuronetics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Neuronetics Inc data using free add-ons & libraries
Get Neuronetics Inc Fundamental Data
Neuronetics Inc Fundamental data includes:
- Net Revenue: 111 M
- EBITDA: -34 989 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuronetics Inc News

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ...


Canaccord Genuity lowers Neuronetics stock price target on margin concerns
Investing.com - Canaccord Genuity lowered its price target on Neuronetics (NASDAQ:STIM) to $7.00 from $8.00 on Wednesday, while maintaining a Buy rating on the stock. The medical device company, wit...

Neuronetics adjusts 2025 gross margin guidance to 48%-50% as Greenbrook revenue mix rises
Earnings Call Insights: Neuronetics (STIM) Q2 2025 MANAGEMENT VIEW * CEO Keith Sullivan highlighted a strong second quarter, stating, “We had a strong second quarter at Neuronetics, both in term...

Neuronetics Inc (NASDAQ:STIM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss
Neuronetics Inc (NASDAQ:STIM [https://www.chartmill.com/stock/quote/STIM/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. Wh...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.